Multiple New Clinical Studies Presented at the American Society of Anesthesiologists Annual Meeting Show Benefits of RAM & PVI

October 17, 2013

IRVINE, CA -- (Marketwired) -- 10/17/13 -- Masimo (NASDAQ: MASI) announced today that four new clinical studies evaluating Masimo noninvasive patient monitoring technologies were presented at the largest gathering of anesthesiologists in the world, the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco. The following studies highlight the positive clinical outcomes and patient safety impact of Masimo's unique rainbow® noninvasive measurement technologies, including RAM™ acoustic respiration rate (RRa™) and PVI®.

RAM

At Stanford University Medical School in Menlo Park, Calif., researchers evaluated RRa and capnography during sedation. The investigators reported: "Of the respiratory pauses detected by a single method, acoustic monitoring had the highest percentage of true positives and the lowest percentage of false positives." They concluded: "When compared to clinical observation or capnography, rainbow® acoustic monitoring (RAM) may provide the best method for detection of respiratory pause during procedures requiring sedation because it has acceptable accuracy for detection of respiratory pause with a low rate of false alarms."1

At Loma Linda University Medical Center in Loma Linda, Calif., researchers found that compared to nasal cannula capnometry (Covidien Capnostream® 20), RAM RRa "detected more true events and had fewer false alarms," adding, "Compared to nasal cannula capnometry, acoustic respiratory monitoring may be a superior monitor of respiration during procedural sedation."2

At Tokyo Women's Medical University, School of Medicine, in Tokyo, Japan, researchers evaluated RAM (RRa), capnometry (CAP), and thoracic impedance pneumography (IMP) and compared them with visual 1-minute chest movement inspection. Investigators concluded: "Continuous respiration rate assessments with RRa correlated well with visual inspection, even for obese patients and patients with respiration rate ≤10 per minute. CAP measurements also showed good correlation with visual chest movement inspection, but the equipment was often removed by some patients because of displeasure or an inserted gastric tube. IMP measurements were inaccurate because of electrode positioning and patient movement and shivering. Therefore, RRa was the most accurate and noninvasive method to monitor respiration rate for detecting apnea, bradypnea, and airway obstruction."3

PVI® with Masimo SET® Pulse Oximetry

At University of California Irvine Medical Center in Irvine, Calif., researchers evaluated whether goal-directed fluid optimization based on PVI can be used reliably intra-operatively in patients undergoing moderate-risk surgery. Investigators concluded, "Goal-directed fluid optimization based on respiratory variation in the pulse oximeter waveform is feasible, and may help to standardize intraoperative fluid management."4

1 Tanaka P, Drover D, Tanaka M. "Detection of Respiratory Pauses by Clinical Observation: Capnography and Acoustic Monitoring" Proceedings of the American Society of Anesthesiologists, October 16, 2013. San Francisco. A5033
2 Applegate R, Lenart J, Malkin M, Macknet M. "Respiratory Pause Detection and False Alarms from Capnography and Acoustic Monitoring in Procedure Related Sedation" Proceedings of the American Society of Anesthesiologists, October 16, 2013. San Francisco. A5027
3 Fukada T, Uenaka Y, Tsuchiya Y, Iwakiri H, Nomura M. "Clinical Evaluation on Acoustic Respiration Rate (RRa™) in PACU Compared With the Conventional Monitoring System" Proceedings of the American Society of Anesthesiologists, October 12, 2013. San Francisco. A1180
4 Canales C, Lee C, Khanh-Van L, Hanacek C, Natalia N, Nguyen C, Le A, Boud R, Rinehart J, Cannesson M. "Feasibility of Goal-Directed Fluid Management Based on Monitoring of Pleth Variability Index (PVI)" Proceedings of the American Society of Anesthesiologists, October 13, 2013. San Francisco. A2211

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo SET® and Masimo rainbow® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb®), PVI®, and acoustic respiration rate (RRa™) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SeDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.

Media Contact:
Mike Drummond
Masimo Corporation
Phone: (949) 297-7434
Email: mdrummond@masimo.com

Source: Masimo